Standard: API 36-32641
SALMONELLA/MAMMALIAN-MICROSOME MUTAGENICITY ASSAY OF THE VAPOR PHASE OF COMMERCIAL HEXANE USING THE DESICCATOR METHODOLOGY
This standard is available for individual purchase.
IHS Standards Expert subscription, simplifies and expedites the process for finding and managing standards by giving you access to standards from over 370 standards developing organizations (SDOs).FEATURES & BENEFITS
- Maximize product development and R&D with direct access to over 1.6 million standards
- Discover new markets: Identify unmet needs and discover next-generation technologies
- Improve quality by leveraging consistent standards to meet customer and market requirements
- Minimize risk: Mitigate liability and better understand compliance regulations
- Boost efficiency: Speed up research, capture and reuse expertise
HOW TO SUBSCRIBE
The mutagenic potential of the vapor phase of Commercial Hexane (or its metabolites) was evaluated using the Desiccator Methodology of the Salmonella/Mammalian-Microsome Mutagenicity Assay. The evaluation is based on the ability of the test article to induce back mutations at selected loci of several strains of Salmonella typhimurium in the presence and absence of exogenous metabolic activation.
In the first phase of the study, the dose range-finding study, tester strain TA100 was exposed to the vapor phase of the test article for 7 hours over a dose range of 9000 to 300 ppm in the presence and absence of microsomal enzymes. No appreciable toxicity was observed over the dose range tested in the presence or absence of microsomal enzymes.
In the second phase of the study, the mutagenicity assay, tester strains TA98, TA100, TA1535, TA1537 and TA1538 were exposed to the vapor phase of the test article for 7 hours over a dose range of 9000 to 600 ppm in the presence and absence of microsomal enzymes. No toxicity or positive mutagenic responses were observed with any of the tester strains either in the presence or absence of microsomal enzymes.
In the third phase of the study, the confirmatory mutagenicity assay, the same tester strains, dose range and experimental conditions as those in the second phase were used. Again, no toxicity or positive mutagenic responses were observed with any of the tester strains either in the presence or absence of microsomal enzymes.
In conclusion, under the experimental conditions of this study, the vapor phase of commercial hexane supplied by the American Petroleum Institute (Formula No. FN 00611A) did not elicit a positive mutagenic response in the Salmonella/Mammalian-Microsome Mutagenicity Assay using the Desiccator Methodology.
|Organization:||American Petroleum Institute|
|Document Number:||api 36-32641|
|Most Recent Revision:||YES|